Cytochrome P450 polymorphisms and drug-induced interstitial lung disease

Author： Schwaiblmair Martin Behr Werner Foerg Wolfgang Berghaus Thomas

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.7, Iss.12, 2011-12, pp. : 1547-1560

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genetic Polymorphisms of Cytochrome P450 and Glutathione S-transferase Associated with Antituberculosis Drug-induced Hepatotoxicity in Chinese Tuberculosis Patients

By Wang T Yu HT Wang W Pan YY He LX Wang ZY

The Journal of International Medical Research, Vol. 38, Iss. 3, 2010-06 ,pp. : 977-986

Field House Publishing

Access to resources Recommend Favorite

Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms

By Ingelman-Sundberg Magnus

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 369, Iss. 1, 2004-01 ,pp. : 89-104

Springer Publishing Company

Access to resources Recommend Favorite

Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury

By Inokuma Shigeko

Expert Opinion on Drug Safety, Vol. 10, Iss. 4, 2011-07 ,pp. : 603-611

Informa Healthcare

Access to resources Recommend Favorite

Drug-induced interstitial lung disease (ILD) associated with statins is a "rare but serious" adverse reaction

Reactions Weekly, Vol. 1, Iss. 1325, 2010-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment

By Brockmöller Jürgen Kirchheiner Julia Meisel Christian Roots Ivar

Pharmacogenomics, Vol. 1, Iss. 2, 2000-05 ,pp. : 125-151

Future Medicine

Access to resources Recommend Favorite